Most recent volume
Translational Medicine in CNS Drug Development is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques to aid researchers in the development of new drugs targeting disorders of the central nervous system. Despite increases in the number of individuals suffering from CNS-related disorders, development and approval of drugs to effectively treat them have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and the CNS to pharmcodynamic measures in both animals and humans. Significantly, major progress has been made in neuroimaging, neurochemical, neurophysiological, and pharmacogenetic/pharmacogenomics biomarker tools that can be used for monitoring diagnosis and progression of diseases, as well as monitoring drug responses by showing central exposure, target engagement, functional responses, and patient enrichment in clinical trials.
With extensive coverage of all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, Translational Medicine in CNS Drug Development is an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for successful development of drugs to treat central nervous system disorders.